Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies Corporation (Nasdaq: DVAX) has granted nonstatutory stock options for 51,000 shares to five new employees as an inducement for employment. The options, with an exercise price of $10.23 per share, were issued on July 1, 2021, and are set to vest over three years. Each option has a 7-year term and vests one-third after one year, with the remainder vesting monthly. This action complies with Nasdaq Listing Rule 5635(c)(4) and is part of the 2021 Inducement Award Plan.
Clover Biopharmaceuticals and Dynavax Technologies have entered a commercial supply agreement for Dynavax's CpG 1018 adjuvant, intended for use in Clover's SCB-2019 COVID-19 vaccine. The agreement is valid through 2022 and includes doses manufactured under prior funding. Clover also announced an advanced purchase agreement with Gavi for up to 414 million doses of SCB-2019 via the COVAX Facility, pending regulatory approvals. The vaccine aims for a product launch by the end of 2021, following clinical trial data expected mid-year.
Clover Biopharmaceuticals has entered into a commercial supply agreement with Dynavax Technologies for the CpG 1018 adjuvant to be used in the production of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). The deal extends until the end of 2022, with doses to be delivered in 2021. Clover also announced an advanced purchase agreement with Gavi for up to 414 million doses through 2022. Pending regulatory approvals, SCB-2019 is expected to launch by the end of 2021 to supply the COVAX Facility and direct government procurement.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the appointment of John Slebir as Senior Vice President and General Counsel on June 28, 2021. To incentivize his employment, the company granted him a non-statutory stock option to purchase 300,000 shares at an exercise price of $9.29 per share, which matches the closing price on the grant date. The option has a 7-year term and vests over three years. This grant complies with Nasdaq Listing Rule 5635(c)(4) as part of Dynavax's 2021 Inducement Award Plan.
Dynavax Technologies Corporation (Nasdaq: DVAX) will have its CEO, Ryan Spencer, present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 p.m. E.T. The presentation will be accessible via webcast through the company's website's 'Events & Presentations' section.
Dynavax specializes in developing novel vaccines, with its first product HEPLISAV-B® approved in the U.S. and EU for hepatitis B prevention in adults. The company is also advancing research on vaccine adjuvants, including collaborations for COVID-19 vaccines.
Dynavax Technologies Corporation (Nasdaq: DVAX) has announced a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, a hepatitis B vaccine, in Germany. The expected launch is set for Q4 2021. HEPLISAV B is the only approved hepatitis B vaccine for adults involving a two-dose regimen completed in one month, boasting a higher seroprotection rate compared to traditional three-dose vaccines. This collaboration capitalizes on Bavarian Nordic's established marketing network in Germany, aimed at improving vaccine accessibility and compliance.
Dynavax Technologies (Nasdaq: DVAX) will participate in a virtual fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 2:40 p.m. C.T. The chat will be led by CEO Ryan Spencer and will be accessible via the company's 'Events & Presentations' page. Dynavax is known for its innovative vaccines, including HEPLISAV-B®, a hepatitis B vaccine approved in both the U.S. and EU, and is advancing its CpG 1018 adjuvant for COVID-19 and other vaccines.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the pricing of $200 million in 2.50% convertible senior notes due 2026. The offering closes on May 13, 2021, with an option for purchasers to buy an additional $30 million. The notes accrue interest semiannually and have a conversion rate of 95.5338 shares per $1,000 principal. The net proceeds, estimated at $195.1 million, will primarily be used to repay outstanding debts. Dynavax will also engage in capped call transactions to mitigate potential stock dilution, with a cap set at $15.80.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced its plan to offer $200 million of convertible senior notes due 2026, with an option for purchasers to buy an additional $30 million. The notes will be unsecured and accrue interest payable semiannually, convertible into cash or stock at Dynavax's discretion. Proceeds will be used to repay existing debt and fund capped call transactions to mitigate stock dilution. The offering is subject to market conditions and is not registered under the Securities Act.
Dynavax Technologies (DVAX) reported a robust first quarter of 2021, achieving total revenues of $83.3 million, a significant increase from $10.9 million in Q1 2020. The company attributed this growth to strong performance from CpG 1018, generating $74.6 million in revenue, while HEPLISAV-B reached $8.3 million despite a decline in vaccine utilization. Notable metrics included an 89.3% seroprotection rate from ongoing clinical trials and a cash position of $232.7 million. The company expects 2021 to be transformational, driven by collaborations and product advancements.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
